The Pursuit of transparency and quality improvement in cost-effectiveness analysis - A case study in disease-modifying drugs for the treatment of multiple Sclerosis

Journal of Managed Care Pharmacy

Volumn 17, Issue 6, 2011, Pages 463-468

  Bell, Christopher F ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; IMMUNOLOGIC FACTOR;

CASE STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HUMAN; MULTIPLE SCLEROSIS; NOTE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); TOTAL QUALITY MANAGEMENT; UNITED STATES; ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; INTERPERSONAL COMMUNICATION; METHODOLOGY; RECURRENT DISEASE; STANDARD; STATISTICAL MODEL;

COST-BENEFIT ANALYSIS; DISCLOSURE; HUMANS; IMMUNOLOGIC FACTORS; MODELS, ECONOMIC; MULTIPLE SCLEROSIS; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE;

EID: 84855748455     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2011.17.6.463     Document Type: Note

References (32)

1. Neumann PJ, Fang CH, Cohen JT. 30 years of pharmaceutical costutility analyses: growth, diversity and methodological improvement. Pharmacoeconomics. 2009;27(10):861-72.
2. Bryan S, Sofaer S, Siegelberg T, Gold M. Has the time come for cost-effectiveness analysis in US health care? Health Econ Policy Law. 2009;4:425-43.
3. Neumann PJ, Palmer JA, Daniels N, Quigley K, Gold MR, Chao S, Panel on Integrating Cost-Effectiveness Considerations into Health Policy Decisions. A strategic plan for integrating cost-effectiveness analysis into the US healthcare system. Am J Manag Care. 2008;14(4):185-88.
4. Fairman KA, Curtiss FR. It's only a pharmacoeconomic model - believe it or not. J Manag Care Pharm. 2008;14(1):83-85. Available at: http://www.amcp.org/JMCP/2008/January/7792/1033.html.
5. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health. 2003;6(1):9-17.
6. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modeling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24(4):355-71.
7. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. June 2008. Available at: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed July 2, 2011.
8. FMCP Format Executive Committee. The AMCP format for formulary submissions version 3.0. J Manag Care Pharm. 2010;16(1-a):S1-30. Available at: http://www.amcp.org/data/jmcp/1007_121%2019%2009(3).pdf.
9. WellPoint Health Technology Assessment Guidelines. Drug Submission Guidelines for Re-evaluation of products, indications and formulations. National Pharmacy and Therapeutics Committee. Version 5.1, October 2005.
10. Watkins J, Sullivan SD, Ramsey S, et al. Inventing a tiered formulary based on the cost-effectiveness of drugs. Presentation at the ISPOR 15th Annual International Meeting. 2010.
11. Becker III RV, Dembek C. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis. J Manag Care Pharm. 2011;17(5):377-81. Available at: http://www.amcp.org/JMCP/2011/June/9742/1033.html. 54.
12. Tappenden P, McCabe C, Simpson E, Chilcott J, Nixon R, Madan J. The clinical effectiveness and cost-effectiveness of interferon-beta and glatiramer acetate in the management of relapsing/remitting and secondary-progressive multiple sclerosis. Agency for Healthcare Research and Quality. October 23, 2006. Available at: https://www.cms.gov/reports/downloads/Tappenden.pdf. Accessed July 2, 2011.
13. Curtiss FR. Pharmacoeconomic modeling of drug therapies for multiple sclerosis - are we building houses on sand? J Manag Care Pharm. 2007;13(3):287-89. Available at: http://www.amcp.org/data/jmcp/287-89.pdf.
14. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet. 2003;361(9357):545-52.
15. Goldberg LD, Edwards NC, Fincher C, Doan QV, AL-Sabbagh A, Meletiche DM. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm. 2009;15(7):543-55. Available at: http://www.amcp.org/data/jmcp/543-555.pdf.
16. Rice GP, Incorvaia B, Munari LM, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database of Sys Rev. 2001;(4):CD002002.
17. Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm. 2007;13(3):245-61. Available at: http://www.amcp.org/data/jmcp/245-61.pdf.
18. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39(3):285-94.
19. Kahn OA, Tselis AC, Kamholz J, Garbern JY, Lewis RA, Lisak RP. A prospective open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur J Neurol. 2001;8(2):141-48.
20. Kahn OA, Tselis AC, Kamholz J, Garbern JY, Lewis RA, Lisak RP. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Mult Scler. 2001;7(6):349-53.
21. Khan O, Zabad R, Caon C, Zvartau-Hind M, Tselis A, Lisak R. Comparative assessment of immunomodulating therapies for relapsingremitting multiple sclerosis. CNS Drugs. 2002;16(8):563-78.
22. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicenter study (INCOMIN). Lancet. 2002;359:1453-60.
23. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002;59(10):1496-506.
24. Nuijten M, Mittendorf T. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective. Clin Ther. 2010;32(4):717-28.
25. Chiao E, Meyere K. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis. Curr Med Res Opin. 2009;25(6):1445-54.
26. Tappenden P, McCabe C, Chilcott J, et al. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. Value Health. 2009;12(5):657-65.
27. Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J. Costeffectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics. 2008;26(7):617-27.
28. Simpson D, Noble S, Perry C. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. CNS Drugs. 2002;16(12):825-50.
29. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health. 2004;7(5):554-68.
30. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology. 1997;49(2):358-63.
31. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ. 2003;326(7388):522-27. Available at: http://www.bmj.com/content/326/7388/522.full.pdf. Accessed July 1, 2011.
32. Nuijten MJ, Hutton J. Cost-effectiveness of interferon beta in multiple sclerosis: a Markov process analysis. Value Health. 2002;5(1):44-54